Background {#Sec1}
==========

Peripheral arterial diseases (PAD), as a member of arteriosclerosis, mostly occur in lower extremity arteries. The morbidity of PAD generally ranged from 3 to 10%, but among the people over 60 years old, it can reach above 15% and it upregulates with aging \[[@CR1]\]. PAD is one of the most serious complications in patients with diabetes mellitus (DM), and the overall prevalence is 21.2% in China \[[@CR2]\]. If not properly treated in the early stage, it is very possible for the patient to suffer from critical limb ischemia (CLI) causing rest pain, ulcer, necrosis, and finally leading to amputation. The rate of amputation among PAD patients is about 1.6\~4.1% with even much higher cardiovascular event incidence and mortality \[[@CR3]--[@CR5]\].

Patients with CLI are commonly treated conventionally at an early stage, such as risk factor control, exercise training, utilizing antiplatelet drugs, and vasodilator \[[@CR6]--[@CR12]\]. But the reconstruction of the blood circulation, which can be achieved by surgery and interventional therapy, presented to be the key to the treatment \[[@CR13], [@CR14]\]. A 5-year survival rate which was less than 50% determined a worrisome prognosis. And when both surgery and interventional therapy is not feasible, amputation may be the last choice of the patients. However, amputation has a high rate of mortality about 25\~50%, of which 5\~20% in perioperational period, and the re-amputation rate is up to 30% \[[@CR15]\]. The risk is significantly raising in patients with DM, for the segmental and diffuse arterial disease as well as the higher risk of cardiovascular event. Since 40% patients have missed the chance for surgery or interventional therapy \[[@CR16]\], a new method is in great demand to reduce the amputation and mortality rate for "no-option" patients.

Autologous stem cell therapy is gradually known as a new therapy. Asahara isolated endothelial progenitor cells (EPCs) from blood in 1997 \[[@CR17]\]. EPCs are a type of adult stem cells, derived from adult bone marrow and is mainly found in the embryo, adult peripheral blood, umbilical cord blood, and bone marrow. EPCs can develop into endothelial cells and then promote revascularization. Methods for isolation of EPCs include magnetic bead selection, density gradient centrifugation, and differential adhesion method and so on. Many animal trials found improved blood flows in ischemic limbs after stem cell implantation \[[@CR18]--[@CR21]\]. Afterward, the therapies of stem cells have been applied to patients with PAD. The first trial in human called therapeutic angiogenesis using cell transplantation (TACT) was performed in Japan \[[@CR22]\]. Since then, a growing body of evidence suggested that autologous stem cell therapy was more effective than standard care/conventional treatment for PAD \[[@CR23]\]. Former systematic review pooled analysis of both randomized controlled trials (RCTs) and non-RCTs; however, studies of different designs cannot be assessed in unification. Therefore, in the present study, we updated the systematic review to evaluate the efficacy and safety of autologous implantation of stem cells for PAD.

Methods {#Sec2}
=======

We followed the recommendations from the Cochrane Collaboration for systematic review and meta-analysis of RCTs and reported according to preferred reporting items for systematic reviews and meta-analyses (PRISMA) statements \[[@CR24]\].

Inclusion criteria and searching strategies {#Sec3}
-------------------------------------------

We searched RCTs involving patients with PAD who were treated with autologous implantation of all kinds of stem cells from electronic medical databases including MEDLINE, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), the Chinese Biomedical Literature Database, China National Knowledge Infrastructure (CNKI), and [ClinicalTrials.gov](http://clinicaltrials.gov) from initial period to September 2018. The MeSH terms were outlined in Additional file [1](#MOESM1){ref-type="media"}: Table S1.

Data extraction and bias assessment {#Sec4}
-----------------------------------

Two investigators selected the studies and extracted data from studies independently. Controversy was resolved by discussion with a third investigator. Extracted data included basic information (author name, study year, country, sample size, design of study, follow-up time), characteristics of patients (sex, age, stage of PAD), methods, intervention details (type and number of stem cells, transplantation routine, intervention in control group), outcomes, and side effect. The bias of the trials included in our study was assessed according to the Cochrane Handbook for Interventions \[[@CR25]\]. The components included allocation sequence generation, allocation concealment, blinding of participants, caregivers, outcome assessors and outcome adjudicators, incomplete outcome data, selective outcome reporting, and other sources of bias. For each item, studies were categorized as high, low, or unclear risk of bias.

Observation index {#Sec5}
-----------------

The primary outcomes consisted of amputation rate, major amputation rate, ulcer healing rate, and side effect. The second outcomes were ankle-brachial index (ABI), transcutaneous oxygen tension (TcO~2~), rest pain score, and pain-free walking distance (PFWD).

Statistical analysis {#Sec6}
--------------------

We performed a meta-analysis of all RCTs using the data from the cell therapy group and control group. Statistical analysis was conducted via RevMan 5.3 and Stata 12.0. Continuous and dichotomous outcome variables were respectively described as mean difference (MD) and odds ratios (OR) with 95% confidence intervals (CI), which were derived from Inverse Variance and Mantel-Haenszel estimate and summarized by Forest plots. Heterogeneity among studies was evaluated by the *I*^2^ parameter and chi-squared tests. Fixed effect model was used for meta-analysis when *I*^2^ values \< 50% and random effect model when *I*^2^ values ≥ 50% as heterogeneity indicated. Incomplete outcome data were analyzed by intention to treat analysis. Sensitivity analyses were conducted to examine the difference between random and fixed effects model as to their effect measures such as OR, relative risk (RR), and risk difference (RD). We explored the publication bias by funnel plots (when the number of included studies more than 9) and Egger's test for continuous endpoints and Harbord's test for dichotomous endpoints.

The GRADE approach was used to evaluate the quality of evidence of each outcome, which was classified as high, moderate, low, and very low after the all-round assessment of study limitations, inconsistency, imprecision, indirectness, and publication bias \[[@CR26]\].

Results {#Sec7}
=======

Study selection and characteristics {#Sec8}
-----------------------------------

Among the 16,977 studies, 27 RCTs \[[@CR22], [@CR27]--[@CR54]\] involving 1186 patients and 1280 limbs were included in our systematic review. The inclusion and exclusion flow was listed in flow Fig. [1](#Fig1){ref-type="fig"}. Among the 27 RCTs, 16 studies were from Asians \[[@CR22], [@CR27], [@CR29]--[@CR35], [@CR37], [@CR43]--[@CR45], [@CR48], [@CR50], [@CR54]\], 7 \[[@CR28], [@CR36], [@CR38], [@CR46], [@CR49], [@CR52], [@CR53]\] from Europeans, and 4 \[[@CR39]--[@CR42], [@CR47], [@CR51]\] from Americans. Patients in the trials were identified as PAD or diabetic foot (DF) with different classifications. Stem cells, including BMMSCs, BMMNCs, BMAC, PBMNC, CD34+ cells, VesCell, PBMCs, and CD133+ cells, were transplanted by intramuscular injection \[[@CR22], [@CR27]--[@CR37], [@CR39]--[@CR51], [@CR53], [@CR54]\] or intra-arterial injection \[[@CR28], [@CR38], [@CR52]\]. The average follow-up time was 4.7 months (1--36 m). Details of studies were listed in Table [1](#Tab1){ref-type="table"}.Fig. 1Flow chart of selection of studiesTable 1Characteristics of clinical trials included in the systematic reviewAuthor (year)CountrySubjectsNo. of patientsNo. of LimbsAverage age (years)No. of maleTreatment strategyFollow-up (months)TreatmentControlTreatmentControlTreatmentControlTreatmentControlTreatment (type, no., route)ControlTateishi-Yuyama et al. (2002) \[[@CR22]\]JapanCLI Fontaine III--IV22222222--------BMMSCs1.5 ± 0.6 × 10^9^IMNo mobilized PBMNCs6Huang et al. (2005) \[[@CR27]\]ChinaDM with CLI Fontaine III--IV1414232471.170.999PBMNCs3 × 10^9^IMConventional therapy3Barć et al. (2006) \[[@CR28]\]PolandCLI14151415--------BMMSCs--IM (14 patients) IA (4 patients)Conventional therapy6Arai et al. (2006) \[[@CR29]\]JapanCLI Fontaine III or IV131213126268117BMMSCs(1--3) × 10^9^IMConventional therapy1Zhang et al. (2007) \[[@CR30]\]ChinaDF Wagner1--3313031301312BMMSCs--IMConventional therapy1Lu et al. (2008) \[[@CR31]\]ChinaDM with CLI FontaineII--IV2525252566.665.51115BMMSCs7.32 × 10^8^--5.61 × 10^9^IMConventional therapy3Dash et al. (2009) \[[@CR32]\]IndiaBuerger's disease and DF (with ulcer)12121212--------BM MSC5.04--7.26 × 10^6^IMConventional therapy3Chen et al. (2009) \[[@CR33]\]ChinaDF Wagner2--42218221865.863.5----BM MSC--IMConventional therapy1Gan et al. (2009) \[[@CR34]\]ChinaDF Wagner1--415152830--------BM MSC(1.35--9.36) × 10^8^IMConventional therapy3--12Shi et al. (2009) \[[@CR35]\]ChinaDM with PAD2525252535-7523BMSCs--IMConventional therapy3Procházka et al. (2010) \[[@CR36]\]Czech RepublicCLI with foot ulcer4254425466.2 ± 10.664.1 ± 8.63642ABMSC0.7--3.83 × 10^9^IMConventional therapy3--4Wen and Huang (2010) \[[@CR37]\]ChinaCLI Fontaine II--V303011260.8 ± 8.661.7 ± 8.32019PBSCs3 × 10^9^IMConventional therapy3--36Walter et al. (2011) \[[@CR38]\]GermanyCLI1921192164.4 ± 1564 ± .5161613BM MNC1.53 × 10^8^IAPlacebo3Iafrati et al. (2011) \[[@CR39]\]Benoit et al. (2011) \[[@CR40]\]AmericaCLI Rutherford4--53414341472.565.7237BMAC3.23 × 10^9^IMPlacebo3--6Powell et al. (2011) \[[@CR41]\]Powell et al (2012) \[[@CR42]\]AmericaCLI4824482469.2 ± 13.267.3 ± 11.63414Ixmyelocel-T--IMPlacebo6--12Lu et al. (2011) \[[@CR43]\]ChinaDM with CLI20 (BMMSCs)21 (BMMNCs)4120 (BMMSCs)21 (BMMNCs)41--------BMMSCs9.3 × 10^8^BMMNs9.6 × 10^8^IMPlacebo6Guan et al. (2011) \[[@CR44]\]ChinaDF Wagner1--43940788069 ± 1645BM-MNC1.27\~8.95) × 108IMConventional therapy6--36Jain et al. (2011) \[[@CR45]\]Indiachronic lower limb wounds in DM252325235458----BMSCs--IMConventional therapy3Ozturk et al. (2012) \[[@CR46]\]TurkeyDM with CLI Fontaine III--IV2020202079.9 ± 9.270.8 ± 8.81613PBMNC9.92 × 10^8^--1.24 × 10^9^IMConventional therapy3Losordo et al. (2012) \[[@CR47]\]AmericaCLI Rutherfod 4--57(LD)9(HD)127(LD)9(HD)1261.8 ± 13.9(LD)69.7 ± 10.9(HD)67.1 ± 14.25(LD)8(HD)6PMCD34+  0.1/Kg (LD)1/Kg (HD)IMPlacebo12Li et al. (2013) \[[@CR48]\]ChinaCLI2929292961 ± 963 ± 102223BM-MNC--IMPlacebo6Szabó et al. (2013) \[[@CR49]\]HungaryFontaine III-IV1010101060.6 ± 8.963.0 ± 12.085VesCell6.64 × 10^7^IMconventional therapy3--24Mohammadzadeh et al. (2013) \[[@CR50]\]IranDM with CLI71471463.5 ± 7.864.2 ± 7.8----PBMCs0.9--1.2 × 10^9^IMPlacebo3Raval et al. (2014) \[[@CR51]\]AmericaCLI7373658562PBCD133+/PLA5 × 10^7^--4 × 10^8^IMPlacebo12Teraa et al. (2015) \[[@CR52]\]NetherlandsCLI Fontaine IIb-IV8179817969655751BMMNC6.57 × 10^8^IAPlacebo6Skóra et al. (2015) \[[@CR53]\]PolandCLI Fontaine IV1616161666.7668.31110BM MNC+VEGF0.77--3.83 × 10^9^IMPentoxifylline3Lu et al. (2016) \[[@CR54]\]ChinaDM with PAD2021202167.227PBSCs--IMConventional therapy6*BMMNC* bone marrow mononuclear cells, *PBMNC* peripheral blood mononuclear cells, *BMAC* bone marrow aspirate concentrate, *BMMSC* bone marrow mesenchymal stem cells, *ABMSC* autologous bone marrow stem cells, *VesCell* peripheral blood-derived autologous angiogenic cell precursors, *IM* intramuscular, *IA* intraarterial, *LD* low dose, *HD* high dose, *VEGF* vascular endothelial growth factor

Risk of bias {#Sec9}
------------

According to Cochrane Handbook, each risk of bias item for each included RCTs and each risk of bias item of all included RCTs were presented in Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}. The figures showed high risk of bias mainly resulted from the lack of allocation concealment, absent blinding, and incomplete outcome data. Among the 27 RCTs, only 6 (22.2%) studies \[[@CR22], [@CR33], [@CR43], [@CR45], [@CR46], [@CR52]\] adequately generated the randomization sequence, 4 (14.8%) \[[@CR22], [@CR40], [@CR45], [@CR49]\] concealed allocation, 8 \[[@CR22], [@CR38], [@CR40], [@CR42], [@CR43], [@CR47], [@CR51], [@CR52]\] (29.6%) blinding of participants and personnel, and 10 (37.0%) \[[@CR22], [@CR29], [@CR38], [@CR40], [@CR42], [@CR43], [@CR47], [@CR48], [@CR51], [@CR52]\] blinding of outcome assessment. Twelve (44.4%) \[[@CR22], [@CR35], [@CR37], [@CR38], [@CR40], [@CR43], [@CR47]--[@CR49], [@CR51], [@CR53], [@CR54]\] trials had no incomplete outcome data, and 22 (81.5%) \[[@CR22], [@CR27]--[@CR29], [@CR31], [@CR32], [@CR35]--[@CR38], [@CR40], [@CR42], [@CR43], [@CR45]--[@CR53]\] were free of selective outcome reporting.Fig. 2Risk of bias summaryFig. 3Risk of bias graph

Amputation rate {#Sec10}
---------------

Among the 27 RCTs, 16 trials \[[@CR27], [@CR28], [@CR31], [@CR36], [@CR38], [@CR40], [@CR42], [@CR43], [@CR46]--[@CR53]\] reported the detailed amputation rate. The meta-analysis showed a lower amputation rate in cell therapy group compared with control (88/425 vs 142/444; OR 0.50, 95% CI 0.36 to 0.69, *I*^2^ = 11%)(Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Forest plot showing the effect of stem cell therapy on amputation rate

Major amputation rate {#Sec11}
---------------------

Eight studies \[[@CR39], [@CR42], [@CR47]--[@CR52]\] reported the detailed major amputation rate. The meta-analysis showed a lower major amputation rate in the stem cell therapy group than control but with no statistical significance (49/232 vs. 60/197; OR 0.66, 95% CI 0.42 to 1.03, *I*^2^ = 0%) (Fig. [5](#Fig5){ref-type="fig"}).Fig. 5Forest plot showing the effect of stem cell therapy on major amputation rate

Ulcer healing rate {#Sec12}
------------------

Fourteen studies \[[@CR27]--[@CR31], [@CR37], [@CR42], [@CR43], [@CR45], [@CR46], [@CR48]--[@CR50], [@CR52]\] reported the detailed ulcer healing rate. The meta-analysis showed a higher ulcer healing rate in the cell therapy group compared with control (170/313 vs 90/310; OR 4.31, 95% CI 2.94 to 6.30, I^2^ = 17%) (Fig. [6](#Fig6){ref-type="fig"}).Fig. 6Forest plot showing the effect of stem cell therapy on ulcer healing rate

ABI {#Sec13}
---

Sixteen studies \[[@CR22], [@CR27], [@CR29], [@CR31], [@CR33]--[@CR35], [@CR37], [@CR43], [@CR44], [@CR46], [@CR47], [@CR49], [@CR50], [@CR53], [@CR54]\] reported the detailed ABI. The meta-analysis showed higher ABI in the cell therapy group compared with control (MD 0.13, 95% CI 0.10 to 0.17, *I*^2^ = 69%) (Fig. [7](#Fig7){ref-type="fig"}).Fig. 7Forest plot showing the effect of stem cell therapy on ABI

TcO~2~ {#Sec14}
------

Eight studies \[[@CR22], [@CR29], [@CR38], [@CR43], [@CR44], [@CR46], [@CR49], [@CR54]\] reported the detailed TcO~2~. The meta-analysis showed higher TcO~2~ in the cell therapy group compared with control (MD 12.62, 95% CI 5.73to 19.51, *I*^2^ = 97%) (Fig. [8](#Fig8){ref-type="fig"}).Fig. 8Forest plot showing the effect of stem cell therapy on TcO~2~

Rest pain score {#Sec15}
---------------

Nine studies \[[@CR27], [@CR28], [@CR31], [@CR33], [@CR34], [@CR38], [@CR43], [@CR44], [@CR46]\] reported the detailed rest pain score. The meta-analysis showed lower rest pain score in the cell therapy group compared with control (MD − 1.61, 95% CI − 2.01 to − 1.21, *I*^2^ = 92%) (Fig. [9](#Fig9){ref-type="fig"}).Fig. 9Forest plot showing the effect of stem cell therapy on rest pain score

Pain-free walking distance {#Sec16}
--------------------------

Only three studies \[[@CR27], [@CR31], [@CR32]\] reported detailed PFWD. The meta-analysis showed that PFWD in stem cell therapy group was higher than the control group (MD 178.25, 95% CI 128.18 to 228.31, *I*^2^ = 0%) (Fig. [10](#Fig10){ref-type="fig"}).Fig. 10Forest plot showing the effect of stem cell therapy on PFWD

Subgroup analysis {#Sec17}
-----------------

Thirteen studies \[[@CR27], [@CR30]--[@CR35], [@CR43]--[@CR46], [@CR50], [@CR54]\] included DM patients. The meta-analysis showed that stem cell therapy could reduce the amputation rate (3/109 vs 32/155; OR 0.17, 95% CI 0.06 to 0.45, *I*^2^ = 0%) (Additional file [2](#MOESM2){ref-type="media"}: Figure S1) and improve the ulcer healing rate (167/305 vs 89/304; OR 4.34, 95% CI 2.96 to 6.38, *I*^2^ = 23%) (Additional file [3](#MOESM3){ref-type="media"}: Figure S2) in DM patients.

Side effect association with cell therapy {#Sec18}
-----------------------------------------

Eight studies \[[@CR22], [@CR33], [@CR37], [@CR40], [@CR42], [@CR43], [@CR47], [@CR52]\] reported the side effect of stem cell therapy. Side effect included slight edema of limbs, transient increase of serum creatine phosphokinase, bleeding, pain, infection, and cellulitis after puncture or injection, hematocrit, proliferative retinopathy, moderate hypotension, and chest distress during mobilization and severe worsening of CLI in the target leg after injection. The most serious side effect was wound sepsis on the injected leg and with the ending of amputation. The detailed side events were showed in Additional file [4](#MOESM4){ref-type="media"}: Table S2.

Publication bias {#Sec19}
----------------

The funnel plot and statistical test showed publication bias in amputation rate, major amputation rate, ABI, and no publication bias in ulcer healing rate, TcO~2~, rest pain score, and PFWD (Additional files [5](#MOESM5){ref-type="media"}, [6](#MOESM6){ref-type="media"}, [7](#MOESM7){ref-type="media"}, and [8](#MOESM8){ref-type="media"}: Figures S3-S6; Additional file [9](#MOESM9){ref-type="media"}: Table S3).

Sensitivity analyses {#Sec20}
--------------------

Results of sensitivity analyses were showed in Additional file [10](#MOESM10){ref-type="media"}: Table S4 and Additional file [11](#MOESM11){ref-type="media"}: Table S5. All the effect measures obtained by random effects do not significantly differ from those by the fixed effect model except for major amputation rate. RD derived from the random model differed from that in the fixed model.

Quality of evidence {#Sec21}
-------------------

GRADE evidence profile is showed in Table [2](#Tab2){ref-type="table"}. All the quality evidence of outcomes were low. The low quality may due to inconsistency, imprecision, and publication bias.Table 2GRADE evidence profile for the outcomesCertainty assessmentNo. of patientsEffectQuality of evidenceImportanceNo. of studiesStudy designRisk of biasInconsistencyIndirectnessImprecisionPublication biasStem cell therapyControl(95% CI)ABI 16RCTNo serious limitationsSerious limitationsNo serious limitationsNo serious limitationsYes396443MD 0.13 (0.10, 0.17)⨁⨁◯◯低ImportantTcO2 8RCTNo serious limitationsSerious limitationsNo serious limitationsNo serious limitationsNo217258MD 12.62 (5.73, 19.51)⨁⨁◯◯低ImportantMajor amputation rate 8RCTNo serious limitationsNo serious limitationsNo serious limitationsSerious limitationsYes49/232 (21.1%)60/197 (305%)OR 0.66 (0.42, 1.03)⨁⨁◯◯低KeyAmputation rate 16RCTNo serious limitationsNo serious limitationsNo serious limitationsSerious limitationsYes88/425 (20.7%)142/444 (32.0%)OR 0.50 \[0.36, 0.69\]⨁⨁◯◯低KeyUlcer healing rate 14RCTNo serious limitationsNo serious limitationsNo serious limitationsSerious limitationsNo170/313 (54.3%)90/310 (29.0%)OR 4.31 \[2.94, 6.30\]⨁⨁◯◯低KeyRest pain score 9RCTNo serious limitationsSerious limitationsNo serious limitationsNo serious limitationsNo260298MD − 1.61 \[− 2.01, − 1.21\]⨁⨁◯◯低ImportantPain-free walking distance 3RCTNo serious limitationsNo serious limitationsNo serious limitationsSerious limitationsNo4849MD 178.25 \[128.18, 228.31\]⨁⨁◯◯低Important

Discussion {#Sec22}
==========

This meta-analysis indicated that autologous implantation of stem cells improved ulcer healing rate, ABI, TcO2, PFWD, and reduced amputation rate and rest pain score compared with standard care/conventional treatment. Stem cell therapy could reduce major amputation rate but with no statistical significance and seemingly no significant improvement in limb salvage (*P* = 0.64). Sensitivity analysis showed instability in the result of major amputation rate which may be related to small sample size and publication bias. Stem cell therapy could reduce amputation rate and improve ulcer healing rate in DM subgroup. The results suggested that stem cell therapy may alter the outcome of intractable CLI to a certain degree.

To our knowledge, this is the systematic review including the most RCTs of autologous implantation of stem cells for PAD up to now. We excluded one study \[[@CR55]\] included in the previous systematic review \[[@CR23]\]. The study used allogeneic bone marrow-derived mesenchymal stem cell for implantation, which did not meet the inclusion criteria. But we included nine studies that were not analyzed in the previous systematic review. The study of Tateishi-Yuyama reported two parts of the experiment and one is RCT \[[@CR22]\]. The other eight studies \[[@CR30], [@CR33]--[@CR35], [@CR37], [@CR44], [@CR45], [@CR53]\] also met the inclusion criteria in every way but were not included in the previous systematic review. In addition, the previous systematic reviews did secondary analysis including non-RCTs and RCTs, but studies of different designs should not be analyzed in a combined manner. In this case, we believe that our results are more reliable than the previous ones. Besides, we are the first to perform the subgroup analysis for patients with DM who bear the increased risk of PAD, segmental and diffuse arterial disease, and cardiovascular event. Most DM patients are not suitable for surgery or interventional therapy, and they may benefit from stem cell therapy.

Our study showed only one serious side effect related to the implantation of stem cells which shall remind us of the importance of aseptic technique during the injection. Due to the short follow-up, a full understanding of the side effect of stem cell implantation calls for further study. There were some observational studies reporting a serious side effect of stem cell therapy. Horie has reported heart failure, myocardial infarction, severe infection, and stroke post-cell therapy \[[@CR56]\]. Moreover, the relationship between the tumor and stem cell therapy remains disputable. Among the 162 patients receiving stem cell implantation in Horie's study \[[@CR56]\], 9 patients had malignant tumor during 24.6 months follow-up. Two patients were diagnosed with a malignant tumor before the study, and the other 7 patients developed a small intestinal tumor, pancreatic cancer, lung cancer, gallbladder carcinoma, gastric cancer, and groin tumor. But this was an observational study and there is no direct cause-and-effect relationship between those events and stem cells therapy. Thus, RCTs of large sample size and longer follow-up time are needed to verify the safety of cell therapy.

There are several limitations in our study. Firstly, most trials have a high or unclear risk of bias so the trials may be underpowered. Low quality of methodology mainly results from inadequate sequence generation, lack of allocation concealment, absent blinding, and incomplete outcome data. Some RCTs mentioned "random" but did not report the specific randomization method. Some RCTs did not use allocation concealment and blinding method. Secondly, several studies had a small sample size and limited information for outcomes, such as adverse events. Thirdly, the included patients, types of stem cells, methods of transplantation, control group, and follow-up time were different among RCTs, which may lead to heterogeneity. The patients in the included studies were identified as having PAD or DF according to a different classification. There were eight types of stem cells including BMMSCs, BMMNCs, BMAC, PBMNC, CD34+ cells, VesCell, PBMCs, and CD133+ cells in our studies. Stem cells were transplanted by intramuscular injection or intra-arterial injection. Besides, the number of stem cells used varied among RCTs and part of studies did not report the number of transplanted stem cells. Stem cells used in the included studies may be the major cause of heterogeneity. Thus, standardization in the transplantation method, stem cell type, and quantity should be valued in transplantation. Treatments in control groups contain non-mobilized peripheral blood mononuclear cells, conventional treatment, and placebo. Follow-up time ranged from 1 to 36 months. These differences lead to great heterogeneity in meta-analysis of ABI, TcO2 and rest pain score. Twenty-seven RCTs included in this study all reported positive results, and we only included studies in English and Chinese, which may lead to publication bias.

Conclusions {#Sec23}
===========

The "no-option" patients with PAD may benefit from stem cells therapy, but there was seemingly no significant improvement in major limb salvage. Due to the low-quality evidence, further researches including larger, randomized, double-blinded, placebo-controlled, multicenter trials with long-term follow-up of high quality are still in demand to prove the efficacy and safety of stem cells therapy for PAD.
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